Skip to Content

Akebia Therapeutics, Inc.

Securities Class Action

  • Date:
  • 5/13/2022
  • Company Name:
  • Akebia Therapeutics, Inc.
  • Stock Symbol:
  • AKBA
  • Class Period:
  • FROM 6/28/2018 TO 9/2/2020
  • Status:
  • Filed
  • Filing Date:
  • 3/14/2022
  • Court:
  • U.S. District Court: Eastern District of New York

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Akebia Therapeutics, Inc. (“Akebia” or the “Company”) (NASDAQ: AKBA) in the United States District Court for the Eastern District of New York on behalf of all persons and entities who purchased or otherwise acquired Akebia securities between June 28, 2018 and September 2, 2020, both dates inclusive (the “Class Period”). Investors have until May 13, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Akebia is a biopharmaceutical company that focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The Company’s lead investigational product candidate is vadadustat, an oral therapy, which is in Phase 3 development for the treatment of anemia due to chronic kidney disease (“CKD”) in dialysis-dependent and non-dialysis dependent (“NDD”) adult patients.
 

Akebia’s Phase 3 clinical programs for vadadustat include, among others, the PRO2TECT program in NDD-CKD patients with anemia (the “PRO2TECT Program”). The PRO2TECT Program’s primary safety endpoint was defined as non-inferiority of vadadustat versus darbepoetin alfa in time to first occurrence of major adverse cardiovascular events (“MACE”).
 

The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) vadadustat was not as safe in treating NDD-CKD patients with anemia as Defendants had represented; (ii) as a result, Defendants overstated the PRO2TECT Program’s clinical prospects; (iii) accordingly, Defendants also overstated vadadustat’s overall commercial and regulatory prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
 

On September 3, 2020, Akebia issued a press release announcing “top-line results” from the PRO2TECT Program, disclosing that “[v]adadustat did not meet the primary safety endpoint of the PRO2TECT program, defined as non-inferiority of vadadustat versus darbepoetin alfa in time to first occurrence of [MACE.]”

On this news, Akebia’s common stock price fell $7.35 per share, or 73.5%, to close at $2.65 per share on September 3, 2020.
 

If you purchased or otherwise acquired Akebia shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Alexandra Raymond by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.

The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Akebia Therapeutics. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: